Pyrilutamide (KX-826) is a topical anti-androgen being developed by Kintor Pharmaceutical for androgenetic alopecia and acne vulgaris. It works by blocking the androgen receptor directly at the follicle, aiming to deliver the anti-androgenic effect of systemic drugs without measurable systemic exposure. The compound has generated significant interest because it targets the same receptor finasteride protects upstream, but through local application rather than circulating hormone reduction. Phase II results from China showed statistically significant hair count increases, and Phase III trials are ongoing. Here is what the clinical data actually shows, how it compares to existing treatments, and why establishing a baseline before any new treatment matters. BaldingAI helps you lock in that baseline with consistent photo tracking so you have objective data if and when new treatments become available.
TL;DR
- Pyrilutamide is a non-steroidal androgen receptor antagonist applied topically to the scalp for androgenetic alopecia.
- Phase II data from China (2022) showed statistically significant hair count improvement versus placebo at 24 weeks.
- Unlike finasteride (a 5-alpha reductase inhibitor), pyrilutamide blocks dihydrotestosterone at the receptor level without reducing systemic DHT.
- It differs from clascoterone in its binding profile and local metabolism rate.
- FDA approval is not imminent; realistic timelines suggest 2026 or later depending on Phase III outcomes.
Important
This article is educational and not medical advice. If you are worried about sudden shedding, scalp symptoms, or side effects, talk to a licensed clinician.
What is pyrilutamide and how does it work?
Pyrilutamide (chemical designation KX-826) is a non-steroidal androgen receptor (AR) antagonist. It binds competitively to the androgen receptor in dermal papilla cells, preventing dihydrotestosterone (DHT) from activating the receptor and triggering the signaling cascade that leads to follicular miniaturization. In simple terms: DHT still gets produced and still reaches the follicle, but pyrilutamide blocks the door so it cannot exert its miniaturizing effect.
This mechanism is distinct from finasteride and dutasteride, which are 5-alpha reductase inhibitors. Those drugs reduce systemic DHT levels by blocking the enzyme that converts testosterone to DHT. The reduction is systemic, which is why finasteride can cause sexual side effects in a subset of users: serum DHT drops by roughly 70%. Pyrilutamide does not alter circulating DHT levels at all. It acts locally at the follicle, and preclinical pharmacokinetic data from Kintor shows rapid local metabolism with minimal systemic absorption.
The concept of topical androgen receptor blockade is not new. Clascoterone (Breezula/Winlevi), developed by Cassiopea, is another topical AR antagonist that received FDA approval for acne in 2020 and has been in trials for androgenetic alopecia. Pyrilutamide and clascoterone share the same general mechanism but differ in chemical structure, binding affinity profiles, and metabolic half-life at the scalp. Kintor has claimed that pyrilutamide has a higher binding affinity for the androgen receptor than clascoterone, though head-to-head comparison data in human hair follicles has not been published.
Phase II clinical trial results
Kintor Pharmaceutical completed a Phase II randomized, double-blind, placebo-controlled trial in China in 2022. The study enrolled 123 male participants with androgenetic alopecia (Norwood-Hamilton grade II through IV) and randomized them to pyrilutamide 0.5% solution or vehicle placebo applied once daily for 24 weeks.
The primary endpoint was change in non-vellus hair count (TAHC) per square centimeter in a target area of the scalp at 24 weeks. The pyrilutamide group showed a mean increase of approximately 22.7 hairs per square centimeter from baseline, compared to a mean increase of approximately 15.1 hairs per square centimeter in the placebo group. The difference was statistically significant (p < 0.05). No serious adverse events were reported, and hormonal panels (including serum testosterone, DHT, FSH, and LH) remained within normal ranges throughout the study, supporting the claim of minimal systemic absorption.
Context matters here. The absolute hair count increase is modest compared to what finasteride trials have demonstrated. In the pivotal finasteride trials (Kaufman et al., 1998, published in the Journal of the American Academy of Dermatology), finasteride 1mg produced a mean increase of approximately 107 hairs in a 5.1 cm2 target area at 24 months, or roughly 21 hairs per square centimeter. Pyrilutamide's 24-week data shows a smaller net effect, but the comparison is imperfect because the trials used different populations, different disease severity baselines, and different measurement timeframes.
How pyrilutamide compares to existing treatments
The key differentiator for pyrilutamide is the side-effect profile, not raw efficacy. Finasteride is effective but carries a risk of sexual side effects (reported in 1.3 to 3.8% of users in clinical trials), which makes some patients reluctant to start it. Dutasteride is more potent but has a similar side-effect concern. Topical finasteride reduces systemic DHT less than oral formulations but does not eliminate it entirely. Pyrilutamide, if the Phase II safety data holds through Phase III, could offer androgen receptor blockade with genuinely negligible systemic hormonal impact.
Compared to clascoterone, the distinction is more nuanced. Both are topical AR antagonists. Clascoterone is a steroidal antiandrogen that is metabolized to cortexolone, while pyrilutamide is non-steroidal with reportedly faster local degradation. The clinical relevance of these pharmacokinetic differences will only become clear when both compounds have robust Phase III data in androgenetic alopecia. As of early 2026, clascoterone's hair loss indication remains in trial, and pyrilutamide's Phase III results have not been fully published.
Minoxidil works through a completely different mechanism (potassium channel opening, vasodilation, prolongation of anagen) and is complementary rather than competing. If pyrilutamide reaches the market, it would most likely be used alongside minoxidil in the same way finasteride currently is: one drug to address the androgenic driver, another to stimulate growth.
Phase III trial status and FDA timeline
Kintor initiated Phase III clinical trials for pyrilutamide in both China and the United States. The U.S. Phase III trial for androgenetic alopecia in males (NCT05564065) began enrollment in late 2022, with a target of over 600 participants across multiple sites. A separate Phase III trial for female androgenetic alopecia has also been registered.
Phase III trials typically require 12 to 24 months for enrollment and treatment, followed by data analysis, regulatory submission, and FDA review. Even with favorable results, a realistic FDA approval timeline is 2027 at the earliest for the AGA indication. Drug development is not linear: unexpected safety signals, manufacturing issues, or inconclusive efficacy data can delay or halt the process entirely. Kintor has faced some regulatory delays in China that have extended their original projected timelines.
It is worth tracking this compound, but not worth waiting for it if you are actively losing hair. Androgenetic alopecia is progressive, and every month of follicular miniaturization makes eventual regrowth more difficult. Starting an evidence-based treatment now and adding pyrilutamide later (if approved) is a more rational strategy than delaying treatment entirely.
The gray market and compounding concerns
Pyrilutamide raw powder has been available through chemical suppliers and gray-market vendors since the Phase II data was published. Some individuals have been self-compounding topical solutions at home or purchasing pre-made formulations from unregulated sources. This carries real risks: without pharmaceutical-grade quality control, the concentration, purity, stability, and vehicle formulation are unknown. Contaminated or incorrectly concentrated batches can cause scalp irritation, systemic exposure, or simply be inactive.
The Phase II safety data is from a controlled clinical setting with pharmaceutical-grade drug product. It cannot be extrapolated to homemade preparations. If you are considering pyrilutamide, the responsible approach is to wait for regulatory approval or enroll in a clinical trial through ClinicalTrials.gov.
Why baseline tracking matters before any new treatment
If you are waiting for pyrilutamide, currently on finasteride, or exploring other options, a documented baseline is the single most useful thing you can do right now. Without before-and-after density data captured under consistent conditions, you cannot objectively evaluate whether a treatment is working, stable, or failing.
Capture photos of your hairline, temples, crown, and part line under the same lighting and angle on day one. Repeat every two to four weeks. BaldingAI standardizes this process so each scan is directly comparable, eliminating the noise that comes from different lighting, wet versus dry hair, and camera distance. When you eventually start a new treatment, whether it is pyrilutamide or something else, you will have months of baseline data showing your natural rate of progression. That data transforms vague impressions into clinical-grade evidence you can share with your dermatologist.
Hair loss treatment is a long timeline. A 24-week trial requires 24 weeks of data. A 12-month finasteride assessment requires 12 months. Starting the tracking habit now means you are ready to evaluate any treatment you try, including ones that do not exist yet.
The bottom line
Pyrilutamide is a legitimate clinical candidate for androgenetic alopecia with a sound mechanistic rationale and encouraging Phase II data. If Phase III trials confirm efficacy and safety, it could become the first topical anti-androgen approved specifically for hair loss in men, filling a real gap for patients who want local androgen receptor blockade without systemic hormonal changes.
But it is not available yet. The Phase II effect size was modest, Phase III outcomes are uncertain, and the gray-market supply is unregulated. If you are losing hair now, evidence-based treatments exist today and should not be deferred in anticipation of a drug that may or may not reach the market on schedule. Track your baseline, start what is proven, and add new tools to your protocol as they become available with proper regulatory backing.
Build your baseline now
BaldingAI tracks your density scores over time so you have objective data ready for any treatment you start, current or future.
Your scans stay private. Delete or export anytime.
Sources: Kaufman et al. 1998, JAAD, Kintor Phase III trial (NCT05564065), Kintor Pharmaceutical pipeline.
